scispace - formally typeset
B

Bruno Loi

Researcher at Catholic University of the Sacred Heart

Publications -  42
Citations -  685

Bruno Loi is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Myocardial infarction & Coronary artery disease. The author has an hindex of 10, co-authored 37 publications receiving 541 citations. Previous affiliations of Bruno Loi include Vita-Salute San Raffaele University.

Papers
More filters
Journal ArticleDOI

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial

Marco Valgimigli, +107 more
- 08 Sep 2018 - 
TL;DR: The prespecified final 1-year outcomes of the MATRIX programme, designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management, are described.
Journal ArticleDOI

Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry).

TL;DR: BVS implantation in STEMI patients can be successfully performed with a high procedural success rate and encouraging midterm outcomes, and larger randomised trials and longer follow-up are needed to assess the potential clinical benefit of BVS versus new-generation DES in this setting.
Journal ArticleDOI

Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.

TL;DR: In this direct prospective comparison, BVS was associated with similar clinical results compared to EES in the STEMI setting and larger and adequately powered randomized trials are needed to fully assess the potential clinical benefit of BVS versus the current standard of care in patients with STEMI.